Tuberc Respir Dis.  2017 Jan;80(1):90-92. 10.4046/trd.2017.80.1.90.

Progression of Tuberculous Pleurisy: From a Lymphocyte-Predominant Free-Flowing Effusion to a Neutrophil-Predominant Loculated Effusion

Affiliations
  • 1Division of Pulmonary and Critical Care Medicine, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea. wjkoh@skku.edu

Abstract

No abstract available.


MeSH Terms

Tuberculosis, Pleural*

Figure

  • Figure 1 Continuous spectrum of tuberculous pleurisy. LDH: lactate dehydrogenase.


Reference

1. Jeon D. Tuberculous pleurisy: an update. Tuberc Respir Dis. 2014; 76:153–159.
2. Lee JY. Diagnosis and treatment of extrapulmonary tuberculosis. Tuberc Respir Dis. 2015; 78:47–55.
3. Korean Centers for Disease Control and Prevention. Notified tuberculosis status in Korea [Internet]. Cheongju: Centers for Disease Control and Prevention;2015. cited 2016 Dec 10. Available from: http://cdc.go.kr/CDC/cms/content/mobile/45/67545_view.html.
4. Light RW. Update on tuberculous pleural effusion. Respirology. 2010; 15:451–458.
5. Lin MT, Wang JY, Yu CJ, Lee LN, Yang PC. TAMI Group. Mycobacterium tuberculosis and polymorphonuclear pleural effusion: incidence and clinical pointers. Respir Med. 2009; 103:820–826.
6. Ruan SY, Chuang YC, Wang JY, Lin JW, Chien JY, Huang CT, et al. Revisiting tuberculous pleurisy: pleural fluid characteristics and diagnostic yield of mycobacterial culture in an endemic area. Thorax. 2012; 67:822–827.
7. Bielsa S, Palma R, Pardina M, Esquerda A, Light RW, Porcel JM. Comparison of polymorphonuclear- and lymphocyterich tuberculous pleural effusions. Int J Tuberc Lung Dis. 2013; 17:85–89.
8. Choi H, Chon HR, Kim K, Kim S, Oh KJ, Jeong SH, et al. Clinical and laboratory differences between lymphocyte- and neutrophil-predominant pleural tuberculosis. PLoS One. 2016; 11:e0165428.
9. Liu SF, Liu JW, Lin MC. Characteristics of patients suffering from tuberculous pleuritis with pleural effusion culture positive and negative for Mycobacterium tuberculosis, and risk factors for fatality. Int J Tuberc Lung Dis. 2005; 9:111–115.
10. Chung CL, Chen CH, Yeh CY, Sheu JR, Chang SC. Early effective drainage in the treatment of loculated tuberculous pleurisy. Eur Respir J. 2008; 31:1261–1267.
11. Cao GQ, Li L, Wang YB, Shi ZZ, Fan DY, Chen HY. Treatment of free-flowing tuberculous pleurisy with intrapleural urokinase. Int J Tuberc Lung Dis. 2015; 19:1395–1400.
12. Barbas CS, Cukier A, de Varvalho CR, Barbas Filho JV, Light RW. The relationship between pleural fluid findings and the development of pleural thickening in patients with pleural tuberculosis. Chest. 1991; 100:1264–1267.
13. Han DH, Song JW, Chung HS, Lee JH. Resolution of residual pleural disease according to time course in tuberculous pleurisy during and after the termination of antituberculosis medication. Chest. 2005; 128:3240–3245.
14. Kwak SM, Park CS, Cho JH, Ryu JS, Kim SK, Chang J, et al. The effects of urokinase instillation therapy via percutaneous transthoracic catheter in loculated tuberculous pleural effusion: a randomized prospective study. Yonsei Med J. 2004; 45:822–828.
15. Ko Y, Kim CH, Chang B, Lee SY, Park SY, Mo EK, et al. Loculated tuberculous pleural effusion: easily identifiable and clinically useful predictor of positive mycobacterial culture from pleural fluid. Tuberc Respir Dis. 2017; 80:35–44.
Full Text Links
  • TRD
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2024 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr